Kornimate/medical-research-clean huggingface dataset:
therapeutic efficacy of topical sirolimus in early stage cutaneous t-cell lymphoma (ctcl)

Conditions: Cutaneous T-cell Lymphoma (CTCL)

Summary: the purpose of this study is to determine whether sirolimus reduces the symptoms of cutaneous t-cell lymphoma (ctcl) and whether it causes any side effects.

this will be a prospective, non-randomized, open label study of topical sirolimus for the treatment of ctcl recurrent or refractory to at least one previous skin directed treatment. the purpose will be evaluation of safety and anti-tumor response as evaluated by serial skin examinations. study duration: for subjects with at least partial remission, treatment will be continued for a maximum of 6 months. all subjects will be followed for 6 months from the time of discontinuation of the study drug or until progression of disease or until a new treatment for ctcl will be started.

Eligibility criteria:
inclusion criteria: * clinically and histologically confirmed diagnosis of ctcl (early stage disease with patches and/or thin plaques covering up to 10%, stage ia) * relapsed or refractory disease after at least one standard skin directed treatment including corticosteroids, topical bexarotene, phototherapy * all subjects must be 18 years of age or older * life expectancy ≥ 6 months, determined by the treating physician * signed informed consent exclusion criteria: * patients currently receiving anticancer therapies or who have received anticancer therapies within 4 weeks of the start of study drug (including topical or systemic glucocorticosteroids, chemotherapy, radiation therapy, antibody based therapy, etc.) * prior treatment with any investigational drug within the preceding 4 weeks * patients receiving chronic, systemic treatment with corticosteroids or another immunosuppressive agent. * female patients who are pregnant or breast feeding, or adults of reproductive potential who are not using effective birth control methods. adequate contraception (oral contraceptives ("the pill"), intrauterine devices (iuds), contraceptive implants under the skin, or contraceptive injections, diaphragms with spermicide and condoms with foam) must be used throughout the trial and for 8 weeks after the last dose of study drug (women of childbearing potential must have a negative urine within 7 days prior to administration of sirolimus). * patients who have received prior treatment with an mtor inhibitor (e.g., sirolimus, temsirolimus, everolimus). * patients with a known hypersensitivity to sirolimus or other rapamycin (e.g., everolimus, temsirolimus) or to its excipient * history of noncompliance to medical regimens * patients unwilling to or unable to comply with the protocol

Keywords: early stage stage 1a cutaneous t-cell lymphoma ctcl
lung tumour volume database

Conditions: Non-Small Cell Lung Cancer

Summary: the main aim is to determine, in patients with locoregional, non-small cell lung cancer (nsclc) treated by definitive radiotherapy, the influence on survival of the volume of primary tumour, as measured from ct imaging, after adjusting for the effect of the current tnm staging system and other known prognostic factors (especially ecog performance and weight loss).

patients with locoregional non small cell lung cancer are registered on study after tumour volumes are outlined by a radiologist and prior to the commencement of any treatment. all patients must have recorded the volume of disease in the primary tumour (and of involved nodes \> 1 cm diameter) as measured from a ct scan performed according to a standard set of conditions. following registration patients are treated with definitive radiotherapy with or without chemotherapy. follow-up will occur with the collection of a minimum amount of data every 12 months from the date of registration on study. quality assurance procedures will be implemented with each site that participates in the study.

Eligibility criteria:
inclusion criteria: must satisfy all of the following * nsclc - histological or cytological diagnosis of non-small cell lung cancer * intra-thoracic disease - disease is confined to the primary site, with or without intrathoracic lymph nodes * ct planning - ct imaging of the thorax has been performed as part of the planning procedure * definitive radiotherapy - it is planned to give definitive radiotherapy with or without chemotherapy (prior to, during or after radiotherapy). definitive radiotherapy is defined as 60 gy in 6 weeks, 50 gy in 4 weeks or at least the equivalent of either of these. the size of each individual; fraction should not exceed 2.5 gy. * measurable disease - the primary tumour and nodes with maximum diameter greater than 1cm represent measurable disease exclusion criteria: a patient satisfying any of the following is ineligible * symptomatic or radiological evidence of metastatic disease * prior treatment for non-small cell lung cancer * surgical resection is part of initial treatment * palliative radiotherapy planned

Keywords: tumour volume prognostic value
comparing patients after eswl treated with ureteral stents versus expulsion therapy with tamsulosin

Conditions: Upper Tract Ureterolithiasis

Summary: the purpose of this study is to see whether patients undergoing eswl, for upper tract urinary stones between 1.5-2.0cm, may be treated by expulsion therapy(tamsulosin) instead of inserting ureteral stents .


Eligibility criteria:
inclusion criteria: * patients above 18 yrs of age. * single urolithiasis up to 2 cm. * kidney/ureters that haven't undergone previous eswl or stent insertion. * normal renal function (creatinine below 100mmo1/1). * sterile urine culture. * normal cbc, blood electrolytes and coagulation studies. * radioopaque stones. exclusion criteria: * more than one stone per kidney unit. * patients receiving steroids, nsaids, calcium channel blockers or alpha blockers on a regular basis. * anatomical anomalies or uromechanical obstruction. * single kidney. * cystinuria. * soldiers or pregnant women. * patients under 18 year

Keywords: expulsion therapy tamsulosin ureterolithiasis stents
cd147 targeting peptide probe for pet imaging in solid tumors

Conditions: Solid Tumor

Summary: the objective of the study is to construct a noninvasive approach using 68ga-dota-ap9 pet/ct to detect the cd147 expression of tumor lesions in patients with solid tumors and to identify patients benefiting from cd147 targeting treatment.


Eligibility criteria:
inclusion criteria: 1. malignant melanoma, liver cancer, colon cancer, pancreatic cancer, breast cancer, gastric cancer, lung cancer, etc., confirmed by histopathology or cytology; 2. age ≥18 and ≤75 years old, male or female; 3. ecog score 0 or 1; 4. expected survival time ≥6 months; 5. there was at least one measurable target lesion according to recist1.1 criteria, and biopsy could be performed within one month before and after pet scan, and the patient could provide 2-3 lesion tissue slides; 6. women of childbearing age (15-49 years) must have had a negative pregnancy test within 7 days before starting testing; women and men of childbearing potential must agree to use effective contraception to avoid pregnancy during the study and for 3 months after the examination; 7. patients recommended by clinicians to undergo pet/ct examination for tumor staging; 8. the subjects could fully understand and voluntarily participate in this experiment, and signed an informed consent. exclusion criteria: 1. pregnant or breastfeeding women, or women planning to become pregnant during the study or within three months after administration, as well as individuals donating sperm or oocytes. 2. individuals known or suspected to be allergic to the investigational drug or any of its components. 3. individuals with significantly abnormal liver or kidney function: serum total bilirubin (tbil) \> 1.5 × 20 µmol/l, or aspartate aminotransferase (ast) \> 2.5 × 45 µmol/l, or alanine aminotransferase (alt) \> 2.5 × 40 µmol/l, or serum creatinine \> 1.5 × 130 µmol/l. 4. unable to cooperate in completing the pet scan, or suffering from claustrophobia or other conditions that prevent cooperation during the pet scan. 5. other situations deemed inappropriate for participation in the trial by the investigator. female patients who are pregnant or breastfeeding.

Keywords: solid cancer cd147 pet imaging
peri-device leakage closure after laao

Conditions: Atrial Fibrillation; Stroke; Bleeding; Leakage of Cardiac Device

Summary: the investigators thought to evaluate the safety and feasibility of peri-device leakage closure after left atrial appendage occlusion (laao, either surgical or interventional) with different devices.

the global burden of atrial fibrillation (af) is high and thromboembolic stroke may be one of the fatal complications. oral anticoagulation has been the mainstay therapy for decades to mitigate stroke risk. however, in poor candidates for long-term anticoagulation non-pharmacological stroke prevention with percutaneous left atrial appendage occlusion (laao) is a considerable treatment option. laa shape and size varies widely and incomplete laa closure or new leaks, due to laa remodeling after the procedure, are observed in up to 30% of patients. those leaks may cause turbulent flow and increase the risk for thrombus formation and subsequent thromboembolic events. however, the clinical significance after percutaneous laao has yet to be determined. if significant leaks are present, patients usually remain on oral anticoagulation. in very few cases, an interventional approach is used to close peri-device leaks. this is the first systematic study, trying to include a respectable number of patients who underwent peri-device leakage closure after laao. in this multi-center, collaborative study the investigators aim to identify different peri-device leak closure strategies with associated clinical outcomes and evaluate safety and feasibility of the procedure.

Eligibility criteria:
inclusion criteria: * patients after interventional or surgical left atrial appendage occlusion with severe leakage, who underwent interventional peri-device leakage closure exclusion criteria: * n/a

Keywords: left atrial appendage occlusion peri-device leakage stroke
an efficacy and safety study of two dose levels of certolizumab pegol (czp) in subjects with plaque psoriasis (pso)

Conditions: Psoriasis; Plaque Psoriasis

Summary: the purpose of this study is to investigate the efficacy and safety of two dose levels of certolizumab pegol in adults with moderate to severe chronic plaque psoriasis when administered every 2 weeks.

this study consists of the following periods: * initial treatment period from week 0 to week 16 * maintenance treatment period from week 16 to week 48 * open-label treatment period from week 48 to week 144 * safety follow-up period from week 144 to week 152

Eligibility criteria:
inclusion criteria: * provided informed consent * adult men or women \>= 18 years * chronic plaque psoriasis for at least 6 months * baseline psoriasis activity and severity index \>= 12 and body surface area \>= 10 % and physician's global assessments score \>= 3 * candidate for systemic psoriasis therapy and/or phototherapy and/or chemophototherapy * other protocol-defined inclusion criteria may apply exclusion criteria: * erythrodermic, guttate, generalized pustular form of psoriasis * history of current, chronic, or recurrent infections of viral, bacterial, or fungal origin as described in the protocol * congestive heart failure * history of a lymphoproliferative disorder including lymphoma or current signs and symptoms suggestive of lymphoproliferative disease * concurrent malignancy or a history of malignancy as described in the protocol * history of, or suspected, demyelinating disease of the central nervous system (e.g., multiple sclerosis or optic neuritis) * female subjects who are breastfeeding, pregnant, or plan to become pregnant during the study or within 5 months following last dose of study drug (in czech republic and germany) and within 3 months for all other countries. male subjects who are planning a partner pregnancy during the study or within 10 weeks following the last dose of study drug * any other condition which, in the investigator's judgment, would make the subject unsuitable for participation in the study * other protocol-defined exclusion criteria may apply

Keywords: certolizumab pegol cimzia psoriasis
the sox trial: compression stockings to prevent the post-thrombotic syndrome

Conditions: Deep Venous Thrombosis

Summary: the purpose of this study is to determine whether elastic compression stockings used for 2 years are effective in preventing the post-thrombotic syndrome in patients with symptomatic proximal deep venous thrombosis.

the post-thrombotic syndrome (pts) is a frequent, burdensome and costly condition that occurs in about one third of patients after an episode of deep vein thrombosis (dvt). affected patients have chronic leg pain and swelling, and sometimes develop skin ulcers. at present, there is little to offer for the treatment of this condition. prevention of pts is the key to reducing its burden on patients and society. elastic compression stockings (ecs) could be helpful in preventing pts, however data on their effectiveness are scarce and conflicting. comparison(s): knee-length, 30-40 mm hg (class ii), graduated ecs worn on the dvt-affected leg daily for 2 years compared to knee-length, inactive (i.e. no compression) stocking, identical in appearance to active ecs, worn on the dvt-affected leg daily for 2 years.

Eligibility criteria:
inclusion criteria: * consecutive patients with a first, symptomatic, objectively confirmed proximal dvt diagnosed within the last 14 days (with or without concurrent distal dvt or pulmonary embolism) * who have no contraindications to standard treatment with heparin and/or warfarin, and * who provide informed consent to participate exclusion criteria: * contraindication to compression stockings * limited lifespan (estimated \< 6 months) * geographic inaccessibility preventing return for follow-up visits * inability to apply stockings daily and unavailability of a caregiver to apply stockings daily * treatment of acute dvt with thrombolytic agents

Keywords: postphlebitic syndrome post-thrombotic syndrome elastic stockings stockings, compression randomized controlled trials quality of life
validation of diagnostic usefulness of the random urine na/k ratio for replacement of 24hr urine na excretion in cirrhotic patients with ascites

Conditions: Liver Cirrhosis; Ascites

Summary: the low sodium intake is important for ascites control in liver cirrhosis patients. therefore, world health organization (who) recommends reduction of sodium (na) to 2g/day for adults. the 24-hour urine na excretion has been regarded as a standard method to estimate the amount of daily dietary sodium intake. however, it is too inconvenient to apply to patients or the general population in practice. for this reason, it has been suggested that a spot urine na/potassium (k) ratio could be replaced with the 24-hour urine na excretion. however, the evidence is not sufficient for that. the investigators will evaluate the usefulness of spot urine na/k ratio to estimate the dietary sodium intake. the investigators will also verify several formulas of estimating the 24-hour na excretion with spot urine na, k, creatinine (cr).

● detailed description: 1. measurements: they should be performed for 2 days (the urine collected within 24 hrs) * 24-hour urine na, k and creatinine (patients were instructed to collect all subsequent urine voids over the next 24-hour period including the ﬁrst void of the following day.) * spot urine na, k, creatinine with the same urine sample in some containers provided to patients. (every urination) 2. calculation * na/k ratio with spot urine na, k * estimating 24-hour urine na with spot urine na, k, cr by using some formulas.

Eligibility criteria:
inclusion criteria: * liver cirrhotic patients with ascites diagnosed by imaging study, biopsy or clinically, regardless of taking diuretics. exclusion criteria: * uncontrolled sepsis or systemic infection. * serum creatinine \>1.5 mg/dl. * patients who are being treated for cancers except hepatocellular carcinoma. * patients who refuse the examine or are not cooperative.

Keywords: liver cirrhosis ascites
laparoscopic assisted transanal resection of rectal cancer with total mesorectal excision

Conditions: Rectal Cancer

Summary: rectal cancer is one of the frequent malignant neoplasms ,total mesorectal excision (tme) has become the gold standard treatment for middle and lower rectal cancers. laparoscopic tme still be difficult in patients with low rectal tumors, narrow pelvic anatomy, male sex or high body mass index . difficult visualization of the pelvic anatomy along with the limitation of rigid laparoscopic instruments may affect the quality of oncological outcomes and increase the risks of injuries during surgery. a down to up approach via transanal total mesorectal excision (tatme) technique may overcome these problems

this clinical trial will be conducted at general surgery department of assiut university hospital . .

Eligibility criteria:
inclusion criteria: * • rectal cancer histologically proven through biopsy * tumours located at least 3 cm from anorectal ring; * local spread restricted to the rectal wall * adequate preoperative sphincter function and continence; * absence of distant metastases. * suitable for elective surgical resection exclusion criteria: * • t4 tumours not responding to neoadjuvant chemo- radiotherapy * patients under 18 years of age * pregnancy * previous rectal surgery (except local excision, endoscopic mucosal resection (emr) or polypectomy) * patients with acute intestinal obstruction * multiple colorectal tumours * familial adenomatosis polyposis coli (fap), hereditary non-polyposis colorectal cancer (hnpcc), crohn's disease or ulcerative colitis * planned synchronous abdominal organ resections * preoperative evidence for distant metastases through imaging of the thorax and abdomen * absolute contraindications to general anaesthesia, * presence of fecal incontinence, * undifferentiated tumors .
an extension study of wa19926 of the long-term safety of tocilizumab (roactemra/actemra) in patients with early moderate to severe rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: this open-label, single arm, multicenter long-term extension study of wa19926 evaluated the safety and efficacy of tocilizumab (roactemra/actemra) in participants with moderate to severe rheumatoid arthritis who completed the 104-week wa19926 core study. eligible patients received tocilizumab 8 mg/kg intravenously every 4 weeks for up to 104 weeks.


Eligibility criteria:
inclusion criteria: * adult participants, \>/= 18 years of age * participants who complete their last wa19926 core study visit (week 104) and who may benefit from study drug treatment according to the investigator's assessment * no current or recent adverse event or laboratory finding preventing the use of the study drug dose of roactemra/actemra 8 mg/kg at baseline visit * women of childbearing potential must agree to use adequate contraception as defined by protocol during the treatment period exclusion criteria: * pregnant females * participants who have withdrawn prematurely from the wa19926 core study for any reason * treatment with any investigational agent or cell-depleting therapies since the last administration of study drug in wa19926 * treatment with an anti-tumor necrosis factor (tnf) or anti-interleukin (il) 1 agent, or a t-cell costimulation modulator since the last administration of study drug in wa19926 * immunization with a live/attenuated vaccine since the last administration of study drug in wa19926 * diagnosis since last wa19926 visit (week 104) of rheumatic autoimmune disease other than rheumatoid arthritis * diagnosis since last wa19926 visit (week 104) of inflammatory joint disease other than rheumatoid arthritis * history of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies, including tocilizumab and its excipients * evidence of severe uncontrolled concomitant disease or disorder * known active or history of recurrent infections * active tuberculosis requiring treatment in the previous 3 years * history of alcohol, drug or chemical abuse since inclusion in the wa19926 study
rehabilitation on equal terms - the remig study

Conditions: Breast Cancer; Breast Neoplasms

Summary: the remig-study aims to increase knowledge about rehabilitation needs, the rehabilitation process of arabic-speaking migrated women with bc, to increase the prerequisites for optimized and equal cancer care. the study aims to map migrated arabic-speaking women's breast cancer rehabilitation with a focus on mental and physical recovery, lifestyle habits as well as satisfaction and goals with the rehabilitation and compare these outcomes with the outcomes of swedish-speaking women. further aim is to explore migrated arabic-speaking women´s experiences and attitudes towards breast cancer rehabilitation.

annually, over 2 million women are diagnosed with breast cancer (bc) globally, of which about 8300 in sweden. today, 20% of the swedish population is foreign born and previous research has shown that women who have migrated are particularly vulnerable when diagnosed with bc. research focusing on migrated women is sparse as they are often excluded from research, but available research shows that experience and management of bc differs depending on ethnicity, that the women to a lesser extent participate in bc screening and rehabilitation and that they have a higher mortality than swedish born women. in recent years, measures to promote early bc diagnosis have been initiated, but knowledge of how optimized rehabilitation should be ensured to promote recovery and reduce the socioeconomic burden is lacking. this study aims to map the rehabilitation of migrant arabic-speaking women with a focus on mental and physical recovery, lifestyle habits and satisfaction and goals with the rehabilitation in the first year after bc diagnosis and compare these outcomes with swedish-speaking women. further to elucidate migrated arabic-speaking women´s experiences and attitudes towards breast cancer rehabilitation.

Eligibility criteria:
inclusion criteria: * undergone treatment for primary breast cancer * ≤18 years old * ability to communicate in the arabic language * written informed consent exclusion criteria: * recurrent disease * palliative diagnosis * pregnancy * prior history of breast cancer * inability to participate in the study due to cognitive impairment

Keywords: rehabilitation
comparison of drugs on headache treatment after ect treatment

Conditions: Mental Disorders

Summary: electroconvulsive treatment (ect) is still actual for treatment of psychiatric symptoms. headache is a very common symptom after this application. the investigators compare the effect of two different drugs for the treatment of headache after ect.

electroconvulsive treatment (ect) is used as an alternative application instead of drug therapy for psychiatric symptoms. ect application is repeated 8-12 times according to the treatment of the patient. this treatment is done in 2 or 3 days intervals. the most adverse effects of ect are headache, memory disorders, myalgia, nausea and vomiting, cardiovascular problems. the most common seen adverse effect is headache with approximately 60% incidence. the main drugs used for the treatment of headache related to ect are nsais and paracetamol. the aim of the current study is to compare the effect of paracetamol and dexketoprofen trometamol on headache treatment after ect.

Eligibility criteria:
inclusion criteria: * all patients who were admitted for ect and gave informed written consent were included in the study. exclusion criteria: * exclusion criteria included patients who gave a history of allergy to acetaminophen, lacked capacity to give informed consent and developed complications such as delirium following ect.